Article Per Year (5 Year)
p-Index From 2021 - 2026
0.23
P-Index
This Author published in this journals
All Journal Nexus Kedokteran Translasional Indonesian Journal of Endocrinology Metabolism and Diabetes (InaJEMD)
Ega Caesaria Pratama Putra
Unknown Affiliation
Health Professions Medicine & Pharmacology Public Health

Published : 2 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 2 Documents
Search

 1 
Molecular Docking Analysis of Family Fabaceae Phytochemistry to Estrogen Receptor Alpha Compared to Tamoxifen in Breast Cancer Ega Caesaria Pratama Putra; Riza Novierta Pesik; Ratna Kusumawati
Nexus Kedokteran Translasional Vol 4, No 1 (2015): Nexus Kedokteran Translasional
Publisher : Fakultas Kedokteran Universitas Sebelas Maret Surakarta

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (14.207 KB)

Abstract

Background: Breast cancer is the second most common cancer.Estrogen is the risk factor of breast cancer. Estrogen receptor ? is expressed by 50-80% of breast cancer. The mechanism of estrogen is mediated by estrogen receptor ? and estrogen receptor ?. Tamoxifen is a selective estrogen receptor modulators (SERMs) that can be bound to the estrogen receptor ?, therefore prevent bonding between estrogen and estrogen receptor ?. Methods: This research used molecular docking analysis of family Fabaceaes Phytochemistry as an inhibitor of estrogen receptor ? activation. This study was observational bioinformatics study to observe interaction between family Fabaceaes phytochemistry and estrogen receptor?. Molecular docking analysis observed binding energy and binding location. This virtual screening analysis was done using PyRx, AutoDock Vina, PyMOL, Open Babel, and UCSF Chimera. Results: We obtained 471 Family Fabaceaes phytochemistry from database, only five compounds that have equal or lower binding energy compared with tamoxifen, that compound werebeta-amyrine (9.6 KJ/Mol), obovatin( 9.6 KJ/Mol), erythrabyssin II (9.6 KJ/Mol), Cajaflavanone (10.2 KJ/Mol), and tomentosanol E (10.5 KJ/Mol). The visualization of binding location analysis showed that only cajaflavanone which have relatively similar binding site location with tamoxifen. Conclusions: Cajaflavanone have a similar characteristic with tamoxifen, and have a potency to be used as partial antagonist of estrogen receptor alpha in breast cancer based molecular docking analysis. However, In vitro and In vivo researchneeded to determine the effectiveness. Keywords: Breast Cancer, Molecular Docking, Fabacea, Tamoxifen, Estrogen Receptor ?
Fibrocalculous Pancreatic Diabetes (FCPD): A Rare Type of Pancreatogenic Diabetes Ega Caesaria Pratama Putra; Eva Niamuzisilawati; Yulia Sekarsari; Brilliant Van Fitof Songso Rhomado; Supriyanto Kartodarsono
‎ InaJEMD - Indonesian Journal of Endocrinology Metabolic and Diabetes Vol. 2 No. 2 (2025): InaJEMD Vol. 2, No. 2
Publisher : PP PERKENI

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.66266/inajemd.v2i2.68

Abstract

FCPD is a rare form of secondary diabetes. FCPD is mainly found in the tropical region; it is characterized by diabetes, chronic abdominal pain, calcification of the pancreas, and steatorrhea. The Incidence of FCPD is often misdiagnosed with type 2 or type 1 diabetes mellitus. A 46-year-old man came with chief complaints of chronic abdominal pain. Abdominal radiography showed calcification in the pancreas. The patient was malnourished. Abdominal X-ray revealed pancreatic calcification, which was confirmed by an abdominal MSCT scan. C-Peptide decreased with an intermediate degree. The patient was given supportive therapy,and insulin was given to control his diabetes. FCPD is a morphological pancreas change caused by chronic tropical pancreatitis. The aetiology of chronic tropical pancreatitis is unknown. FCPD can be diagnosed by history taking and supporting examinations such as abdominal X-ray examination, ultrasound and abdominal CT Scan. C-peptide was examined to assess the function of pancreatic beta cells. The primary treatment for FCPD is insulin therapy; metformin or Sulfonylureas can be used in the early phase of diabetes. In reducing pain, non-steroidal analgesics are used as an option. The use of pancreatic enzyme supplementation can improve the nutritional status of patients. FCPD is a rare case, occurring mainly in tropical countries and in people who are malnourished. The primary treatment for FCPD is insulin therapy.
Co-Authors Brilliant Van Fitof Songso Rhomado Eva Niamuzisilawati Ratna Kusumawati Riza Novierta Pesik Supriyanto Kartodarsono Yulia Sekarsari